Correlation Between Tempest Therapeutics and Moleculin Biotech
Can any of the company-specific risk be diversified away by investing in both Tempest Therapeutics and Moleculin Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tempest Therapeutics and Moleculin Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tempest Therapeutics and Moleculin Biotech, you can compare the effects of market volatilities on Tempest Therapeutics and Moleculin Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tempest Therapeutics with a short position of Moleculin Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tempest Therapeutics and Moleculin Biotech.
Diversification Opportunities for Tempest Therapeutics and Moleculin Biotech
-0.34 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Tempest and Moleculin is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Tempest Therapeutics and Moleculin Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Moleculin Biotech and Tempest Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tempest Therapeutics are associated (or correlated) with Moleculin Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Moleculin Biotech has no effect on the direction of Tempest Therapeutics i.e., Tempest Therapeutics and Moleculin Biotech go up and down completely randomly.
Pair Corralation between Tempest Therapeutics and Moleculin Biotech
Given the investment horizon of 90 days Tempest Therapeutics is expected to under-perform the Moleculin Biotech. But the stock apears to be less risky and, when comparing its historical volatility, Tempest Therapeutics is 1.09 times less risky than Moleculin Biotech. The stock trades about -0.16 of its potential returns per unit of risk. The Moleculin Biotech is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest 236.00 in Moleculin Biotech on September 4, 2024 and sell it today you would earn a total of 33.00 from holding Moleculin Biotech or generate 13.98% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Tempest Therapeutics vs. Moleculin Biotech
Performance |
| Timeline |
| Tempest Therapeutics |
| Moleculin Biotech |
Tempest Therapeutics and Moleculin Biotech Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Tempest Therapeutics and Moleculin Biotech
The main advantage of trading using opposite Tempest Therapeutics and Moleculin Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tempest Therapeutics position performs unexpectedly, Moleculin Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moleculin Biotech will offset losses from the drop in Moleculin Biotech's long position.| Tempest Therapeutics vs. Candel Therapeutics | Tempest Therapeutics vs. Cingulate Warrants | Tempest Therapeutics vs. Unicycive Therapeutics | Tempest Therapeutics vs. Cardio Diagnostics Holdings |
| Moleculin Biotech vs. Pulmatrix | Moleculin Biotech vs. Cyclacel Pharmaceuticals | Moleculin Biotech vs. Akari Therapeutics PLC | Moleculin Biotech vs. Bio Path Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Complementary Tools
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |